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Objective: Although clinical guidelines recommend monotherapy with antidepressants (ADs) 
for major depression, polypharmacy with benzodiazepines (BDZs) remains an issue. Risks 
associated with such treatments include tolerance and dependence, among others. We 
assessed the prevalence and determinants of AD and BDZ utilization among Canadians who 
experienced a major depressive episode (MDE) in the previous 12 months, and determined 
the association of seeing a psychiatrist on the utilization of ADs and BDZs.
Method: Data were drawn from the 2002 Canadian Community Health Survey: Health 
and Well-Being, a nationally representative sample of Canadians aged 15 years and 
older. Descriptive statistics quantified utilization, while logistic regression identified factors 
associated with utilization, such as sociodemographic characteristics or type of physician 
seen. Sampling weights and bootstrap variance estimations were used for all analysis.
Results: The overall prevalence of AD and BDZ utilization was 49.3% of respondents 
who experienced an MDE in the past 12 months and reported AD use. Key determinants 
of utilization were younger age and unemployment in the past week (OR 2.6; P < 0.001). 
Being seen by a psychiatrist increased utilization (OR 2.5; P < 0.001), possibly because 
psychiatrists were seeing patients with severe depression.
Conclusion: A large proportion of people with past-year MDEs utilized ADs and BDZs. 
It is unclear how much of this is appropriate given that evidence-based clinical guidelines 
recommend monotherapy with ADs in the treatment of major depression.
Can J Psychiatry. 2011;56(11):667–676.
Clinical Implications
• In Canada, the utilization of ADs and BDZs is high among people with MDEs, 
suggesting lack of adherence to clinical guidelines.
• High-risk people should be closely monitored for effectiveness of treatment and 
overall well-being.
• Reasons for the utilization should be determined to help develop strategies to 
promote uptake of the evidence-based guidelines.
Limitations
• We used cross-sectional self-reported data, which may be subject to reporting bias.
• Indications for medication use to know the diagnosis of the disease were not 
accounted for in the data.
• The survey was conducted in 2002; therefore, study findings may not reflect current 
clinical practice.
Key Words: antidepressants, benzodiazepines, utilization, major depressive 
episodes, Canada
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Depression is one of the leading causes of disability, worldwide. It has a profound effect both on the life 
of the people and on the health care system, and thereby 
represents a major public health challenge.1–3 The CCHS 
1.2 revealed that 4.8% of Canadians experienced MDEs in 
the past year.4 The pharmacological treatment of choice is 
therapy with ADs,5 and this is reflected in data from the 
CCHS 1.2, where 40.4% of Canadians who had experienced 
MDEs in the past year reported using ADs.6
The therapeutic management of major depression becomes 
more complex with the presence of comorbid anxiety. 
A meta-analysis of RCTs on the use of ADs alone, and 
in conjunction with BDZs, among adults with major 
depression and (or) anxiety and (or) insomnia identified 
combination therapy as superior to ADs alone at 1 to 4 
weeks of the treatment.7 For example, combination therapy 
minimized dropouts from side effects, compared with 
ADs alone. However, the advantage of the combination 
therapy, compared with ADs alone, diminished between 
6 to 12 weeks of the treatment and the meta-analysis failed 
to elucidate patient outcomes beyond 12 weeks.7 The 
authors suggested physicians should carefully weigh the 
use of ADs in combination with BDZs to treat comorbid 
anxiety or insomnia in patients with major depression, such 
that the potential benefits offset the risks of the combination 
therapy for individual patients.7
Even in the presence of comorbid anxiety, clinical practice 
guidelines on pharmacotherapeutic management of major 
depression do not recommend the long-term use of BDZs 
to treat comorbid symptoms of anxiety or insomnia.5 This 
is based on several findings. First, ADs have equal or 
greater efficacy than BDZs to treat anxiety disorders, such 
as panic disorder, and are the first choice in the treatment 
of panic disorder and agoraphobia.8–12 In particular, ADs 
with anxiolytic properties are better tolerated and a more 
appropriate intervention to manage anxiety symptoms 
concurrent with major depression in the longer term.7–13 
By contrast, BDZs are not superior to a control treatment 
in reducing the depressive symptomatology that often 
accompanies panic disorder.10 Last, the long-term use of 
BDZs is not recommended because of the risks associated 
with their use, including dependence.14
Despite this, the use of BDZs in conjunction with ADs is 
common, with prevalence ranging from 9.8% to 62.9%.15–25 
These studies15–25 identified potential factors that increase 
concurrent use of BDZs and ADs, such as 1) type of AD 
(SSRIs), 2) females, 3) older age, 4) presence of comorbid 
anxiety, and 5) seeing a psychiatrist. However, none of 
these studies15–25 examined utilization of ADs and BDZs 
among people with past-year MDEs.
A further study26 found that utilization of ADs and BDZs was 
more likely in respondents who had been depressed in the 
previous year, compared with those who had not. However, 
this study did not report in detail on factors associated with 
such coprescribing in major depression.26 One explanation 
is that physicians sometimes prescribe BDZs while 
initiating the treatment for depression to mitigate early 
symptoms but then fail to withdraw BDZ therapy following 
treatment response.27 Such widespread use of BDZs to 
treat comorbid anxiety in depressed people is of significant 
concern, given the potential risks of combination therapy, 
compared with therapeutic benefits.7 These potential risks 
include tolerance, dependence, and the higher risk of falls, 
especially among seniors.7
There is also evidence of variation between countries. A 
comparison between Nova Scotia and Australia found double 
the use of BDZs to ADs in Nova Scotia.28 However, findings 
from Nova Scotia may not generalize to the entire country. The 
study was also restricted to people aged 65 years and older.28
We employed a nationwide community survey to 
determine the prevalence and determinants of ADs and 
BDZs utilization in Canadians aged 15 years and older 
who have experienced MDEs in the past 12 months. We 
also determined the association of seeing a psychiatrist 
(compared with a family doctor or other health profession) 
on the utilization of ADs and BDZs. We compared the 
observed use of ADs and BDZs with the Canadian Network 
for Mood and Anxiety Treatments (commonly referred to as 
CANMAT) clinical practice guidelines published in 2001, 
as the survey (CCHS 1.2) was conducted in 2002.5,29
Method
Survey
We analyzed data from the CCHS 1.2,29 a cross-sectional 
survey of a nationally representative sample of people 
aged 15 years and older, conducted by Statistics Canada 
between May and December of 2002. The survey collected 
information on the prevalence of mental disorders, such 
as major depression, mania, panic disorder, agoraphobia, 
and social phobia, as well as health service use related to 
these disorders. The survey achieved a 77% (n = 36 984) 
response rate. Most of the interviews were conducted face 
to face, and about 14% of the survey was conducted over 
the phone.29 We selected people who experienced an MDE 
in the past 12 months before the interview and had used 
ADs in the past 12 months (Figure 1). Our study sample 
comprised 823 people who met the inclusion criteria.
Abbreviations
AD antidepressant
BDZ benzodiazepine
CCHS 1.2 Canadian Community Health Survey:  
 Mental Health and Well-Being
MDE major depressive episode
RCT randomized controlled trial
SSRI selective serotonin reuptake inhibitor
WMH-CIDI World Mental Health–Composite International  
 Diagnostic Interview
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Measures
Mental Illness. Questions on mental disorders were 
determined using a Canadian modified version of the CIDI 
developed for the WMH 2000 Survey, the WMH-CIDI. 
The WMH-CIDI generates both lifetime and past 12-month 
mental health profiles based on the definitions of the 
International Classification of Diseases, 10th Revision, and 
the Diagnostic and Statistical Manual of Mental Disorders, 
Fourth Edition.29
Medication Use. Participants were asked about their 
psychotropic medication use in the 12 months before the 
interview. Indications for medication use were not recorded 
in the CCHS 1.2 data; hence medications were assumed to 
be used for the conditions in which they were prescribed. 
AD use was based on the question, “In the past 12 months, 
that is, from date 1 year ago to yesterday, did you take 
antidepressants (such as Prozac, Paxil, or Effexor)?”30 
Similarly, BDZ use was based on the question, “In the past 
12 months, that is, from date 1 year ago to yesterday, did 
you take any medication to reduce anxiety or nervousness 
(such as Ativan, Valium, or Serax)?”30 Responses included 
dichotomous measures: yes and no.30
Physician Speciality. The key determinant in the study 
measured the association of physician speciality on 
utilization of ADs and BDZs. Physician specialty 
was derived from the question “Who prescribed the 
medication?” Responses include “psychiatrist,” “family 
doctor or general practitioner,” “other medical doctor (for 
example, cardiologist, gynaecologist, and urologist),” and 
“other health professional.”30 This variable was recoded 
to a dichotomy to compare psychiatrists with other health 
professionals (“family doctor or general practitioner” and 
“other” combined).
Determinants. Potential determinants of AD and BDZ 
utilization included were: age (recoded to aged 15 to 
35 years, aged 36 to 50 years, aged 51 to 65 years, or 
aged 66 years and older); gender (coded either male or 
female); marital status (coded as married, living common-
law, widowed, separated, divorced, and single, or never 
married); education (coded as less than secondary school, 
secondary school graduation, post-secondary, or post-
secondary graduation); self-perceived generally physical 
health (coded as excellent, very good, good, fair, or poor); 
household income (coded into quintiles as lowest income 
quintile, lower middle income quintile, middle income 
quintile, upper middle income quintile, or highest income 
quintile); employment status in the last week (coded as 
yes or no); urban or rural residence (coded as urban or 
rural); regional or provincial residence (coded as Atlantic 
[Newfoundland and Labrador, Prince Edward Island, 
Nova Scotia, and New Brunswick], Prairies [Manitoba and 
Saskatchewan], Western [Alberta and British Columbia], 
Quebec, and Ontario); and health insurance coverage 
(coded as a dichotomous measures: yes or no).30
Statistical Analysis
Secondary data analysis was performed in 3 stages to 
examine the association between the determinants and 
the dependent variable. In the first stage, the prevalence 
of AD and BDZ utilization in the study population was 
Figure 1  Schematic representation of study population
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Table 1  Frequency and prevalence of AD and BDZ utilization by people 
who had experienced MDEs in the past 12 months
 
Characteristic
Unweighted 
n = 423
Weighted 
%
Bootstrap 
95% CI
Sex
Male 140 51.0 42.3–59.7
Female 283 48.4 42.4–54.5
Age, years
15–35 146 48.8 41.4–56.3
36–50 158 49.7 41.2–58.3
51–65 100 52.8 42.4–63.2
≥66 019 a31.4a 14.7–48.1
Marital status
Married 107 49.0 40.5–57.5
Common law 032 a47.6a 30.9–64.3
Widowed 026 a44.6a 25.5–63.8
Separated 056 a44.1a 29.2–59.0
Divorced 067 59.4 47.5–71.3
Single (never married) 135 48.3 38.5–58.1
Location
Urban 363 50.1 44.7–55.6
Rural 060 44.0 32.5–55.5
Self-perceived health
Excellent 016 46.8 25.7–67.9
Very good 080 43.4 32.7–54.1
Good 125 47.5 39.1–55.9
Fair 126 49.8 40.9–58.7
Poor 076 66.3 53.3–79.3
Education
<Secondary school 096 45.0 36.0–53.9
Secondary school graduation 073 45.7 34.8–56.7
Post-secondary 040 51.2 36.3–66.1
Post-secondary graduation 212 52.2 44.7–59.8
Household income
Lowest 071 63.9 52.8–75.0
Lower middle 066 53.2 40.0–66.5
Middle 101 53.0 43.8–62.3
Upper middle 101 44.4 34.5–54.3
Highest 058 49.1 37.7–60.6
Employment in past week
Yes 146 37.9 30.3–45.5
No 200 57.5 50.6–64.4
Insurance coverage for medications
Yes 333 49.5 44.0–55.0
No 089 48.5 38.3–58.7
Region or province
Atlantic 078 55.0 44.7–65.4
Prairies 035 39.3 24.9–53.8
Western 086 41.7 32.0–51.4
Quebec 070 53.0 39.7–66.2
Ontario 154 53.8 46.4–61.2
Medication prescribed by psychiatrist
Yes 153 65.7 57.4–73.9
No 264 42.2 36.2–48.2
a Low estimate precision owing to high sampling variability; interpret with caution
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examined. Descriptive statistics were generated to provide 
an overview of utilization across population subgroups 
based on sociodemographic and other measures.
In the second stage, unadjusted analysis were performed 
to identify predictors of AD and BDZ utilization, 
incorporating covariates such as sex, age, marital status, 
location, employment in past week, insurance coverage 
for medications, education, household income, self-
perceived health, provinces, and medication prescribed by 
a psychiatrist. Based on the unadjusted analysis, covariates 
with P ≤ 0.2 were further analyzed adjusting for age, 
employment in last week, household income, self-perceived 
health, and provinces. In the third stage, a logistic regression 
model was constructed to examine the mediating effect31,32 
of having a prescription from a psychiatrist, compared with 
other health profession, on utilization, while adjusting for 
employment in past week, age, and region or province.
Multi-stage design effects of the survey were taken into 
account to obtain precise estimates that were representative 
of the target population. Sampling weights and bootstrap 
methods to estimate 95% confidence intervals, as provided 
by Statistics Canada, were employed in all analysis.29 
Statistical significance for all analysis was set to 2-sided 
alpha of less than 0.05. Data analysis was conducted 
using SAS software.33 All the analysis were conducted at 
the Atlantic Research Data Centre, located at Dalhousie 
University, to maintain confidentiality of the data.34 Our 
study was approved by The Health Sciences Human 
Research Ethics Board, Dalhousie University, Halifax, 
Nova Scotia.
Results
Table 1 summarizes the utilization of ADs and BDZs among 
people who experienced MDEs in the past 12 months. The 
data suggest 49.3% (95% CI 44.4% to 54.2%; unweighted 
n = 423) of respondents who had experienced an MDE in 
the past 12 months and were taking ADs were also taking 
BDZs; a high prevalence rate given the recommendations 
of the clinical practice guidelines.5
Table 2 presents unadjusted and adjusted results for the 
utilization of ADs and BDZs among Canadians who had 
experienced an MDE in the past 12 months. Adjusted results 
indicate that people without a job (OR 2.3; P < 0.001) and those 
aged 65 years and younger were significantly more likely to 
utilize ADs and BDZs. Table 3 adds psychiatrist to the analysis 
to assess changes in the odds of utilization, adjusting for other 
covariates. People whose medications were prescribed by a 
psychiatrist were significantly more likely to utilize ADs and 
BDZs (OR 2.5; P < 0.001) (Model 2).
We explored the possibility that one reason for combined 
therapy being prescribed by psychiatrists was that they saw 
patients with more serious cases of depression. We did this by 
examining people who screened positive for depression but 
did not experience an MDE in the past year; that is, people who 
did not meet the threshold to qualify for clinical depression. 
Among these people, having medications prescribed by 
a psychiatrist (OR 1.3; 95% CI 0.88 to 1.89; P = 0.19) 
or family physician or GP (OR 0.87; 95% CI 0.6 to 1.23; 
P = 0.46) had no effect on the likelihood of AD and BDZ 
utilization.
Discussion
Comparisons With Other Studies
Our research is one of the first population-based studies 
to assess the utilization of ADs and BDZs among people 
with major depression, and the first national Canadian 
study to do so. Results gleaned from our study indicate 
about 49% of respondents who reported an MDE in the past 
12 months and reported AD use also reported BDZ use. 
These population-based findings are generally consistent 
with rates of between 9.8% and 62.9% in studies from 
mostly clinical settings.15–25 This variation in prevalence 
likely arises from differences in setting (for example, 
community, primary care, or secondary care) and diagnostic 
criteria. We specifically assessed people with MDEs in the 
past 12 months, while other studies conducted in United 
States and Europe have employed varying definitions of 
depression.15–25
Factors Associated With the Utilization of  
ADs and BDZs
As has been found elsewhere, we were unable to 
demonstrate differences in the utilization of ADs and BDZs 
between males and females.20,22 This seems surprising 
given that ADs and BDZs are generally prescribed more 
often to females.6,23,24,35,36 The reasons for this discrepancy 
are unclear and warrant further investigation. However, 
we found that AD and BDZ utilization was associated with 
being aged 64 years and younger, which has been shown 
in studies in the United States where the odds of using 
ADs or BDZs among people treated for depression was 
higher among people aged 45 to 64 years than those aged 
65 and older.20,22 AD and BDZ utilization being less among 
people aged 65 years and older is encouraging, given that 
older people are particularly susceptible to the adverse 
effects of polypharmacy. Further, variation in AD and BDZ 
utilization across age groups identified in our study and 
the extant literature may arise from differences in patient 
characteristics, study designs, and access to prescription 
medications.
Employment status was found to be associated with 
the utilization of ADs and BDZs. People identifying 
themselves as unemployed were more likely to use ADs 
and BDZs, a finding similar to preceding studies.24,35,36 We 
also found people who had medications prescribed by a 
psychiatrist were twice as likely to utilize ADs and BDZs 
(OR 2.5; P < 0.001), a finding uncovered in a national 
study completed in the United States.20 One explanation for 
this finding is that psychiatrists treat patients with a higher 
severity of depression and (or) concurrent anxiety,7,20,37 
where it may be appropriate to add a short course of BDZs 
for up to 1 month.
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Table 2  Logistic regression analysis of AD and BDZ utilization by people who had experienced MDEs 
in the past 12 months
 Unadjusted Adjusted
Independent variable OR 95% CIa P  OR 95% CIa P
Sex
Males 1.1 0.7–1.7 0.64  —  —  — 
Age, years
15–35 2.1 0.9–5.0 0.10 1.50 1.3–16.6 0.02
36–50 2.2 0.9–5.2 0.09 1.40 1.2–14.3 0.02
51–65 2.4 1.0–6.12 0.06 3.60 1.0–12.7 0.04
Marital status
Married 1.2 0.5–2.8 0.69  —  —  — 
Common law 1.2 0.4–3.1 0.82  —  —  — 
Separated 1.0 0.4–2.6 0.97  —  —  — 
Divorced 1.8 0.7–4.7 0.21  —  —  — 
Single 1.2 0.5–2.9 0.75  —  —  — 
Location
Urban 1.3 0.7–2.2 0.36  —  —  — 
Employment in past week
No 2.3 1.5–3.5 <0.001 2.30 1.5–3.6 <0.001
Insurance coverage for medications
Yes 1.0 0.6–1.7 0.86  —  —  — 
Education
Secondary school graduation 1.0 0.6–1.8 0.95  —  —  — 
Some post-secondary 1.3 0.6–2.5 0.51  —  —  — 
Post-secondary graduation 1.3 0.8–2.1 0.24  —  —  — 
Household income, Can $
Lowest 2.0 1.1–3.7 0.02 1.40 0.7–2.8 0.33
Lower middle 1.3 0.6–2.6 0.45 1.20 0.6–2.6 0.58
Middle 1.3 0.8–2.2 0.35 1.10 0.6–2.0 0.74
Upper middle 0.9 0.5–1.6 0.74 0.90 0.5–1.6 0.79
Self perceived health
Very good 0.9 0.3–2.4 0.79 1.06 0.4–3.1 0.9
Good 1.0 0.4–2.7 0.95 1.09 0.4–3.1 0.86
Fair 1.1 0.4–3.0 0.81 1.08 0.4–3.2 0.88
Poor 2.2 0.8–6.5 0.14 2.01 0.6–6.6 0.24
Region or province
Atlantic 1.9 0.9–4.0 0.10 1.77 0.8–3.9 0.16
Western 1.1 0.5–2.3 0.81 1.05 0.5–2.2 0.89
Quebec 1.7 0.8–3.9 0.21 1.70 0.8–3.8 0.17
Ontario 1.8 0.9–3.5 0.10 1.68 0.8–3.3 0.13
Medication prescribed by psychiatrist
Yes 2.6 1.6–4.1 <0.001  —  —  — 
a Bootstrap confidence intervals
— = no data
Reference groups for statistical analyses: sex = females; age = ≥66 years; marital status = widowed;
location = rural; employment in past week = yes; insurance coverage for medications = no;  
education = less than secondary school graduation; household income = highest; 
self-perceived health = excellent; region or province = Prairies; medication prescribed by psychiatrist = no
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Another explanation is that physicians are unaware or fail 
to adhere to guidelines,5 such as those recommending ADs 
alone for the pharmacotherapy of MDEs. Of course, it is 
possible that guidelines developed for specific disorders 
may not reflect the realities of clinical practice where 
there are higher levels of comorbid anxiety. For instance, 
guidelines often rely on RCTs that do not include typical 
patients in the community, owing to stringent inclusion and 
exclusion criteria. Accordingly, physicians may often initiate 
treatment for depression (and [or] concurrent anxiety) with 
ADs and BDZs to allow for quick relief of symptoms.38,39 
While this treatment is often meant to be pursued for the 
short term, physicians may fail to withdraw BDZ therapy 
based on improvements in the patient’s condition over time. 
Physicians may also accede to request by their patients for 
BDZ to preserve their therapeutic relationship.27,39 There is 
also better compliance with AD therapy among depressed 
people when they have also received a BDZ.7
Reasons for Utilization of ADs and BDZs
There may be systemic reasons for the relatively high rates 
of AD and BDZ utilization. One may be due to high overall 
rates of SSRIs and BDZs whether or not these are used in 
combination.6,19,40,41 The high rates of BDZ prescription 
in Canada, compared with other jurisdictions, have been 
attributed to the easy availability in terms of reimbursement 
and the wide range of BDZs listed in the Canadian provincial 
formularies.41,42
Although clinical guidelines5 in effect at the time of the 
survey recommended ADs alone for the pharmacotherapy 
of MDEs, our study clearly suggests significant use of 
ADs in conjunction with BDZs by Canadians who had 
experienced an MDE in the past year. Our study serves as 
a marker for potential divergence between recommended 
clinical guidelines5 and actual care received by Canadians 
who have experienced MDEs. The combination therapy of 
ADs and BDZs among high-risk people (such as seniors) 
makes them more vulnerable to a range of adverse events 
(that is, oversedation, poor concentration, and mental 
confusion),7,14 which could lead to complications, such as 
falls among seniors.7,43
Findings from our study should be interpreted with caution 
owing to the following limitations. First, the data were 
self-reported and possibly subject to recall bias. However, 
previous research reveals good concordance between 
self-reported and actual medication use.44–47 Second, 
the CCHS 1.2 was conducted in 2002, only 1 year after 
clinical guidelines that recommended monotherapy for 
major depression. Previous studies have reported that the 
uptake of evidence-based guidelines into clinical practice 
may take many years.48 Third, severity of the disease has 
not been fully accounted for in the CCHS 1.2 data. As 
such, our study was unable to identify possible referrals 
of patients with severe cases by family physicians to 
psychiatrists, and the higher rate of coprescribing of ADs 
and BDZs by psychiatrists may be reflective of such 
referrals. Further support for this explanation comes from 
our finding that in patients with subclinical cases, there 
was no association between being seen by a psychiatrist 
and being coprescribed a BDZ. Fourth, the duration of use 
for both medications was not recorded in the CCHS 1.2, 
which may result in an overestimation of the rate of AD and 
Table 3  Logistic regression analysis of AD and BDZ utilization on key determinants, and access to a 
psychiatrist, among people who had experienced MDEs in the past 12 months (parsimonious model)
Model 1 Model 2
Independent variable AOR 95% CIa P   AOR 95% CIa P
Age, years
15–35 3.4 1.4–8.4 <0.01 3.4 1.3–9.1 0.01
36–50 3.6 1.5–8.6 <0.01 3.4 1.3–9.1 0.01
51–65 3.3 1.3–8.3 0.01 3.0 1.1–8.3 0.03
Employment in past week
No 2.6 1.7–4.0 <0.001 2.3 1.5–3.6 <0.001
Region or province
Atlantic 1.7 0.8–3.6 0.16 2.1 1.0–4.5 0.04
Western 1.0 0.5–2.0 0.94 1.2 0.6–2.3 0.58
Quebec 1.5 0.7–3.3 0.26 2.1 1.0–4.4 0.06
Ontario 1.7 0.9–3.2 0.11 1.9 1.0–3.5 0.05
Medication prescribed by psychiatrist
Yes  —  —  — 2.5 1.5–3.9 <0.001
a Bootstrap confidence intervals
— = no data 
Reference groups for statistical analyses: age = ≥66 years; employment in past week = yes; region or province = Prairies;
medication prescribed by psychiatrist = no
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BDZ utilization. Although the CCHS 1.2 failed to provide 
data on the length of therapy, other work suggests that up 
to 60% of primary care patients prescribed BDZs receive 
this on a long-term basis of more than 8 weeks; 15% have 
at least 7 prescribing events.49 Moreover, patients with 
major depression make up a large proportion of long-term 
BDZ users (60%).50 Therefore, we assume short-term BDZ 
use (that is, 8 weeks or more) would not have contributed 
greatly to the prevalence rates we report. The prevalence 
of AD and BDZ therapy identified in our study is similar 
to the rates reported elsewhere for long-term use of BDZs, 
providing further support for this assumption.21,22 Fifth, we 
were unable to establish the influence of anxiety on the 
study findings as the data failed to account for whether any 
anxiety disorders were concurrent with MDEs or if they 
occurred at different times within the past year. Finally, it 
is important to acknowledge that there is need for further 
research on the long-term risks and benefits of BDZs, 
especially as compared with ADs, and some physicians 
continue to prescribe BDZs for durations exceeding 
guidelines, especially in refractory patients.51–55
Conclusion
To conclude, our research is one of the first population-
based studies from Canada to assess the utilization of ADs 
and BDZs among people with major depression. Our study 
suggests extensive use of ADs and BDZs by the respondents. 
This underscores a potential lack of concordance between 
medication use to treat MDEs and the recommendations 
of Clinical Guidelines for the Treatment of Depressive 
Disorders5 on pharmacotherapeutic management of major 
depression.
Further studies are indicated to more fully understand 
patient- and physician-based factors associated with the 
combined use of ADs and BDZs. Methods could include 
qualitative research as well as quantitative analysis of 
administrative data. Initiatives to bridge the gap between 
research findings and medication prescribing should be 
explored.
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Résumé : L’utilisation d’antidépresseurs et de benzodiazépines chez les personnes 
souffrant de dépression majeure au Canada
Objectif : Bien que les guides cliniques recommandent une monothérapie d’antidépresseurs (AD) pour 
la dépression majeure, la polypharmacie avec benzodiazépines (BDZ) demeure en question. Les risques 
associés à ces traitements comprennent la tolérance et la dépendance, entre autres. Nous avons évalué 
la prévalence et les déterminants de l’utilisation d’AD et de BDZ chez les Canadiens qui ont subi un 
épisode de dépression majeure (EDM) dans les 12 derniers mois, et déterminé l’association entre la 
consultation d’un psychiatre et l’utilisation d’AD et de BDZ.
Méthode : Les données ont été tirées de l’Enquête sur la santé dans les collectivités canadiennes, Santé 
mentale et bien-être de 2002, un échantillon représentatif à l’échelle nationale des Canadiens de 15 ans 
et plus. Les statistiques descriptives quantifiaient l’utilisation, tandis que la régression logistique identifiait 
les facteurs associés à l’utilisation, comme les caractéristiques sociodémographiques ou le type de 
médecin consulté. Les poids d’échantillonnage et les estimations de variance par la méthode bootstrap 
ont été utilisés pour toutes les analyses.
Résultats : La prévalence globale de l’utilisation des AD et des BDZ était de 49,3 % des répondants 
qui ont eu un EDM dans les 12 mois précédents et qui ont déclaré utiliser des AD. Les principaux 
déterminants de l’utilisation étaient le jeune âge et le chômage dans la semaine précédente (RC 2,6;  
P < 0,001). Consulter un psychiatre augmentait l’utilisation (RC 2,5; P < 0,001), possiblement parce que 
les psychiatres voyaient des patients souffrant de dépression grave.
Conclusion : Une grande proportion des personnes ayant souffert d’EDM l’année précédente utilisaient 
des AD et des BDZ. La mesure dans laquelle cela est approprié n’est pas claire, étant donné que les 
guides cliniques fondés sur des données probantes recommandent une monothérapie d’antidépresseurs 
pour le traitement de la dépression majeure. 
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